Approval is “Mile Stone of Public Health in Acute Pain Management,” said Jacqueline Corrign-Curay, JD, MD, and FDA drug evaluation research center. “The new non -opioid analgesic treatment class of acute pain provides opportunities to alleviate specific risks related to the use of opioids for pain and provide another treatment option to patients.”
Vertex, behind this drug, stated that the wholesale cost of 50 mg tablets that worked for 12 hours was $ 15.50, the daily cost was $ 31, and the weekly expenses were $ 217. The cost is cheaper and higher than the general opioid. However, the report of the clinical economic Review Institute in December shows that if the price is set to $ 420 a week, considering the ability to avoid the opioid poisoning case, the Suzetrigin is “slightly more opioid. It was estimated to reduce costs.
In the statement, Vertex’s CEO and president, Reshma Kewallramani, said, “We have trumpeted as a historic milestone of 80 million in the United States, which prescribes severe acute pain drugs from the middle of the year. (W) E has the opportunity to change the paradigm of acute pain management and establish a new standard care.
